11-deoxy-11-imino-4-deoxy-3,4-[2-spiro-tetrahydrothiopyran-4-yl]-(1H)-imidazo-(2,5-dihydro)rifamycin S | 1574166-71-4

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 大环内酰胺类
• 英文名称: 11-deoxy-11-imino-4-deoxy-3,4-[2-spiro-tetrahydrothiopyran-4-yl]-(1H)-imidazo-(2,5-dihydro)rifamycin S
• CAS: 1574166-71-4
• 化学式: C₄₂H₅₄N₄O₁₀S
• 分子量: 806.978
• InChiKey: REAGIYOFBWRURD-OKPBYMMHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.58
• 重原子数：
  57.0
• 可旋转键数：
  2.0
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  209.09
• 氢给体数：
  6.0
• 氢受体数：
  14.0

文献信息

• [EN] COMPOSITIONS AND METHODS FOR DRUG-SENSITIZATION OR INHIBITION OF A CANCER CELL<br/>[FR] COMPOSITIONS ET PROCÉDÉS DE SENSIBILISATION AUX MÉDICAMENTS OU D'INHIBITION D'UNE CELLULE CANCÉREUSE
  申请人：TEXAS A & M UNIV SYS

  公开号：WO2014036309A1

  公开（公告）日：2014-03-06

  The disclosure provides rifamycin and rifamycin derivative compositions, including rifabutin and rifabutin derivative compositions able to cause drug-sensitization in a cancer cell or inhibition of a cancer cell. The disclosure also provides methods of administering such compositions to cancer cells to sensitize them to drugs, such as chemotherapeutics, or directly inhibit them. The disclosure also provides methods of administering such compositions to increase reactive oxygen species (ROS), particularly superoxides, in cancer cells. The disclosure further provides methods of determining whether a cancer will respond to chemotherapeutics and whether to administer rifamycin or a rifamycin derivative based on ROS levels in cancer cells of a patient.

  本披露提供利福霉素和利福霉素衍生物组合物，包括能够导致癌细胞药物敏感性或抑制癌细胞的利福布丁和利福布丁衍生物组合物。本披露还提供了将这些组合物直接注入癌细胞或注射药物，如化疗药物，以增强癌细胞对药物的敏感性的方法。本披露还提供了将这些组合物注入癌细胞以增加反应性氧化物种（ROS），尤其是超氧化物，在癌细胞中的方法。本披露还提供了一种确定癌细胞是否对化疗药物产生反应以及是否基于患者癌细胞中的ROS水平注射利福霉素或利福霉素衍生物的方法。
• Compositions and methods for drug sensitization of parasites
  申请人：Sacchettini James C.

  公开号：US10226455B2

  公开（公告）日：2019-03-12

  Compositions and methods for inhibiting and/or sensitizing or re-sensitizing a parasite to an antiparasitic drug are provided. The compositions can comprise a rifamycin derivative or a pharmaceutically acceptable salt, hydrate, or prodrug thereof in an amount and formulation sufficient to inhibit or induce drug-sensitization in a parasite. The methods can comprise administering a rifamycin derivative or a pharmaceutically acceptable salt, hydrate, or prodrug thereof to a parasite in an amount and formulation sufficient to inhibit or induce drug-sensitization in the parasite.

  本研究提供了抑制寄生虫和/或使寄生虫对抗寄生虫药物敏感或再敏感的组合物和方法。这些组合物可以包含利福霉素衍生物或其药学上可接受的盐、水合物或原药，其用量和制剂足以抑制寄生虫或诱导寄生虫对药物敏感。所述方法可包括向寄生虫施用利福霉素衍生物或其药学上可接受的盐、水合物或原药，其用量和制剂足以抑制或诱导寄生虫药敏化。
• COMPOSITIONS AND METHODS FOR DRUG-SENSITIZATION OR INHIBITION OF A CANCER CELL
  申请人：Sacchettini James

  公开号：US20140314878A1

  公开（公告）日：2014-10-23

  The disclosure provides rifamycin and rifamycin derivative compositions, including rifabutin and rifabutin derivative compositions able to cause drug-sensitization in a cancer cell or inhibition of a cancer cell. The disclosure also provides methods of administering such compositions to cancer cells to sensitize them to drugs, such as chemotherapeutics, or directly inhibit them. The disclosure also provides methods of administering such compositions to increase reactive oxygen species (ROS), particularly superoxides, in cancer cells. The disclosure further provides methods of determining whether a cancer will respond to chemotherapeutics and whether to administer rifamycin or a rifamycin derivative based on ROS levels in cancer cells of a patient.
• COMPOSITIONS AND METHODS FOR DRUG SENSITIZATION OF PARASITES
  申请人：Sacchettini James C.

  公开号：US20160354358A1

  公开（公告）日：2016-12-08

  Compositions and methods for inhibiting and/or sensitizing or re-sensitizing a parasite to an antiparasitic drug are provided. The compositions can comprise a rifamycin derivative or a pharmaceutically acceptable salt, hydrate, or prodrug thereof in an amount and formulation sufficient to inhibit or induce drug-sensitization in a parasite. The methods can comprise administering a rifamycin derivative or a pharmaceutically acceptable salt, hydrate, or prodrug thereof to a parasite in an amount and formulation sufficient to inhibit or induce drug-sensitization in the parasite.
• US9134329B2
  申请人：——

  公开号：US9134329B2

  公开（公告）日：2015-09-15